{"id":"akf-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Unknown"}]},"_chembl":{"chemblId":"CHEMBL4638824","moleculeType":"Unknown","molecularWeight":"364.45"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AKF-1 works by binding to the molecular target, which results in the desired therapeutic effect.","oneSentence":"AKF-1 is a small molecule drug that targets the molecular target.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:00:21.939Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Unknown"}]},"trialDetails":[{"nctId":"NCT01561521","phase":"PHASE3","title":"An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Akorn, Inc.","startDate":"2012-03","conditions":"Allergic Conjunctivitis","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AKF-1","genericName":"AKF-1","companyName":"Akorn, Inc.","companyId":"akorn-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AKF-1 is a small molecule drug that targets the molecular target. Used for Unknown.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}